Thread Rating:
  • 0 Vote(s) - 0 Average
  • 1
  • 2
  • 3
  • 4
  • 5
An In-Depth Look At Organovo
We are initiating coverage of Organovo, Inc. (ONVO.PK) with an 'Outperform' rating. We believe the company's pioneering efforts into three-dimensional bioprinting have the potential to dramatically improve drug discovery and development. Organovo's bioprinter, the NovoGen MMX, is a first-in-class device capable of creating three-dimensional living tissue that can be used to model a specific disease or pathway, build complex pharmacokinetic and toxicology assays, and even potentially create human organs for transplantation or other regenerative medicine applications.

An In-Depth Look At Organovo

Forum Jump:

Users browsing this thread: 1 Guest(s)